@Getoutofmyway1 I think that is mostly due to itch being the primary factor for decreased quality of life for patients. It's not really positioned to clear up skin but rather to dampen the symptom burden.
$NKTR has set its own bar for Rezpeg off-drug data and it is below my bar for differentiation as a first-line choice.
Management has now mentioned on three separate occasions (Q3 call, UBS, Jefferies) that about 50% of responders holding EASI-75 12 months after stopping rezpeg would be a success in the Q1 2027 readout.
In my thread I set my bar at Ebglyss, where 66% of responders held EASI-75 nine months after being switched to placebo. If rezpeg clears that at 12 months, it is clearly differentiated imo. At 50% I don’t think you can say that. It would still be a good result, but it doesn’t tell us that rezpeg is more durable than Ebglyss. Beating Ebglyss is where the bigger opportunity is, as rezpeg could then be positioned as a drug that may give patients long remissions off treatment, and that would be a reason to use it as a first option.
Durable responses could support long dosing intervals, but that won’t be unique by the time rezpeg launches, as Ebglyss is already approved for maintenance every eight weeks and zumilokibart has shown activity dosed every 12 and 24 weeks. A case can be made for patients who have already been on a biologic, where its novel mechanism is the argument and infrequent dosing adds to it. But I am skeptical that infrequent dosing positions it as a competitive first option.
Management says the 50% comes from Dupixent’s SOLO-CONTINUE at nine months, and I’m not sure where they are getting that figure from. In the JAMA Dermatology paper, the arm switched to placebo held EASI-75 in 30.4% (24/79), and the arms that stayed on drug held 55% to 72%. It doesn’t change much since their bar is above the real Dupixent number anyway, but Ebglyss is the harder comparison.
No position on Nektar.
$NKTR OPPY PT $140 Off-treatment AD data in 1Q27 could further differentiate rezpeg’s durability.
NKTR plans to assess clinical responses through 52-weeks after treatment
cessation, following one full year of therapy. Mgt highlighted ~50%
EASI-75 retention at 12-months as potentially differentiated vs. dupilumab’s nine-
month withdrawal data. believe sustained responses could support quarterly
maintenance, with 6-month dosing potentially appropriate for deep responders,
pending further clinical evaluation.
@Getoutofmyway1 Yea agreed, market doesn’t want to give them credit. Seems odd to me even though I’m skeptical about first option use. AtD is a huge market.
Durability is the second place rezpeg could win.
Maintenance frequency and benefit after stopping treatment are different things. Ebglyss is now approved for Q8W maintenance, and zumilokibart has shown Q12W and Q24W activity. Rezpeg’s own Q12W data look good, but it keeps it level with the field at best, not ahead of it.
Sustained benefit off drug would be. The idea that Treg expansion could modify the disease is plausible but unproven in the literature. In Rezpeg's Phase 1b, 71% of Week 12 responders kept EASI-75 and 80% kept vIGA 0/1 at week 48, 36 weeks after stopping treatment.
The catch is that AtD waxes and wanes, and responses can linger after stopping other drugs too. In ADvocate, ebglyss responders switched to placebo still kept EASI-75 at 66% and IGA 0/1 at 48% over the same 36 weeks.
So the bar for “durable off drug” is higher than it looks, and the Q1 2027 readout is where rezpeg has to clear it.
If it clears that bar, that’s a reason to use rezpeg earlier in treatment, not just after other drugs fail, and a way into the biologic-naive market where it otherwise has no edge. If it doesn't, rezpeg is competing for a contested niche with weaker induction data.
5/5
This is research commentary, not financial advice. I have no position in Nektar at the time of writing.
I think that would be amazing and I think it’s not likely. The map of biology is still largely a blank page and randomized human proof is the long pole in the tent. I am excited about the use of AI in our sector but progress will likely be steady and incremental.
The long pole point is the one tech people miss. ML has been used in drug discovery since well before the current AI boom, and Ph 1 to approval still sits around 8-9% (IQVIA). Most programs fail on efficacy in Ph 2, because we still don't fully understand how pathways interact inside a cell, how disease changes them, or how that plays out across the whole body. Working in silico isn't working in a randomized trial, and better reasoning can't fill a gap in the biological data. AI can speed up getting to the clinic, but it can't yet predict how a drug will behave across thousands of genetically different patients. Only trials can show that.
Planning and executing the reactions to make a complex molecule (a “route”) is one of the hardest jobs in organic chemistry.
From one image of each of four molecules, with no internet and with code as its only tool, Claude wrote a complete route in about half an hour.
I agree to some extent. I think it would make its case as the preferred treatment option for patients uncontrolled with biologics due to its MOA. That’s a big market on its own.
But in terms of efficacy, it’s ph2b data was below SOC, and Lilly’s and Abbvie’s drugs have infrequent dosing as well.
I see it’s only other route of differentiation to be a positive readout from its off-drug durability in Q1 2027.
Would be interested in hearing if you can think it can differentiate in other ways?
https://t.co/tzWqJb2GAf
So what could that niche be worth for $NKTR?
~2.7M US moderate-to-severe AtD patients, ~20% on advanced therapy, and ~30% of those still uncontrolled. That's ~160K patients, and at ~$30K net per year, roughly a $5B market.
Not all of that is up for grabs. Many of those patients will cycle through another biologic or a JAK first, and rezpeg would have to earn its place in that sequence. The niche won’t be uncontested either, as Pfizer is already testing tilrekimig in biologic-experienced patients.
But tilrekimig is still a type 2 drug. Rezpeg sitting outside the IL-4/IL-13 cascade and the JAK pathway gives it a real argument for patients who aren’t controlled on those drugs, and a path to substantial share of this niche.
But it has to prove it works there. That's why I see ZENITH AD-3 as the pivotal readout for Rezpeg's value. It's specifically enrolling patients previously treated with biologics and/or JAK inhibitors.
To be clear, $5B is the size of the niche where rezpeg is differentiated, not its total opportunity. It will pick up some biologic-naive patients too, but there it's competing in a crowded market without a clear edge. What could change that is durability.
4/5
Does Treg expansion prove $NKTR's rezpeg mechanism is working in Atopic Derm?
Not on its own. Rezpeg has shown efficacy in AtD, but Treg expansion alone doesn't tell us how much those cells contribute to the clinical response.
Some Tregs in AtD suppress poorly, and rezpeg has produced larger expansions in diseases where its clinical results were weaker.
Nektar has evidence supporting the mechanism. The unresolved question is which functional subsets drive the benefit in AtD patients, and how much of the response they explain.
1/5
People in the comments are missing the point here from @dawallach. Biology is very different than math.
Math is ultimately established through logical proofs. In biology/drug discovery, you need empirical evidence from a system which is highly complex and is difficult to fully observe. For example, we still don't fully understand how the systems within a human cell interact, or how those interactions change in diseases, let alone across the entire human body.
AI will likely accelerate drug discovery, but the issue is that designing new drugs or finding interesting biological pathways isn't equivalent to curing diseases. AI's reasoning capabilities have improved substantially, and people naturally assume that it will translate to more drugs being discovered. But reasoning is not the bottleneck. It's the quality of the data on which AI is trained and applied to, and whether its predictions actually translate into clinical outcomes. A drug working in vitro or in silico doesn't mean it will work in a randomized clinical trial, as BioX knows too well. Today, the probability from Ph 1 to approval stands around 8-9% (IQVIA).
AI also isn't new to biotech/pharma. Machine learning was being applied to biology and drug discovery long before the recent AI boom. Yet, rates of approval have stayed consistent for years. We simply don't have the data yet to fully understand how it all relates.
Because of uncertainty around biology, developing a new drug often takes close to a decade. Regulators require a mountain of evidence that demonstrate a drug is safe and effective in patients, for good reason. But that takes time. AI can accelerate parts of that process, but it can't eliminate the need for clinical evidence.
There will be many great discoveries in the next 10 years, and AI will likely play a major role in them. But there's a huge difference between accelerating drug discovery and curing all diseases. To say all diseases will be cured is a stretch.
https://t.co/I05J4NEuaf
When Demis Hassabis talks about curing all diseases within 10 years, @dawallach says scientists who have spent decades studying these problems aren't necessarily buying it.
"When [scientists] hear AI people say smart things, they go, 'Cool, yeah, let's run it.' Everyone respects Demis."
"But when Demis says we're gonna cure all diseases in 10 years, I think people who have two PhDs and have been doing this for 40 years go, 'Come on, man.'"
"You're giving a sort of false hope to a lot of people who are legitimately out there suffering or have a loved one who's on death's doorstep. That's a little messed up."
Fair point. AA has shown clear efficacy signals as well. My broader point is that the size of the Treg expansion alone isn’t enough to judge how well the drug will work, and identifying the Treg population and its contribution to response would strengthen the evidence for the drug's MOA.
Rezpeg's clinical results in AtD give the Treg approach credibility. It doesn't mean that another drug producing a larger expansion will work better, or that the same approach will succeed in another disease.
That is why the functional gap matters. Understanding which cells account for the benefit would help explain where rezpeg works and what another Treg drug would need to improve on.
A competitor reporting a bigger expansion shouldn’t be automatically assumed to deliver more useful suppression in patients.
5/5
This is research commentary, not financial advice. No position in Nektar at the time of writing.
Nektar does have evidence beyond expansion.
In REZOLVE-AD, blood CD25bright Treg frequency rose up to roughly sixfold. In skin, Treg-associated genes including FOXP3 and IL2RA increased. Early serum changes in IL-10 and TGF-β1 (signals Tregs use to suppress immune activity) correlated with later EASI improvement.
Rezpeg-expanded Tregs have also been shown to suppress other T cells in a healthy-volunteer experiment. So there is a reasonable basis for thinking these cells contribute to the response.
What remains unresolved is their function in AtD patients. The skin gene-expression data don't identify which cells are producing the signal or show how well they suppress inflammation.
The evidence supports the Treg mechanism. It doesn't yet explain which parts of that population account for the benefit.
4/5
Lebri's half-life is ~25 days, so only about 18 of its 36 weeks were really drug-free. Amli's 28 weeks run from re-randomization (32 from the last dose), and with its long PK tail patients were only drug-free for roughly the final 8 weeks. Rezpeg's half-life is 1–2 weeks, so about 45 of its 52 weeks should be drug-free. I would imagine both would be lower at 52 weeks.
What really matters for $NKTR’s Rezpeg in Atopic Derm?
The AtD market is crowded but lucrative:
- Dupixent is on pace to generate ~US$24B across all indications in 2026, driven largely by AtD sales.
- Lilly’s Ebglyss, ~2 years after launch, is approaching blockbuster status.
- Rinvoq has billion dollar sales in AtD despite its boxed warning.
For Rezpeg, week 16 induction efficacy won’t differentiate it, but there are two places where it could.
1/5
Durability is the second place rezpeg could win.
Maintenance frequency and benefit after stopping treatment are different things. Ebglyss is now approved for Q8W maintenance, and zumilokibart has shown Q12W and Q24W activity. Rezpeg’s own Q12W data look good, but it keeps it level with the field at best, not ahead of it.
Sustained benefit off drug would be. The idea that Treg expansion could modify the disease is plausible but unproven in the literature. In Rezpeg's Phase 1b, 71% of Week 12 responders kept EASI-75 and 80% kept vIGA 0/1 at week 48, 36 weeks after stopping treatment.
The catch is that AtD waxes and wanes, and responses can linger after stopping other drugs too. In ADvocate, ebglyss responders switched to placebo still kept EASI-75 at 66% and IGA 0/1 at 48% over the same 36 weeks.
So the bar for “durable off drug” is higher than it looks, and the Q1 2027 readout is where rezpeg has to clear it.
If it clears that bar, that’s a reason to use rezpeg earlier in treatment, not just after other drugs fail, and a way into the biologic-naive market where it otherwise has no edge. If it doesn't, rezpeg is competing for a contested niche with weaker induction data.
5/5
This is research commentary, not financial advice. I have no position in Nektar at the time of writing.
So what could that niche be worth for $NKTR?
~2.7M US moderate-to-severe AtD patients, ~20% on advanced therapy, and ~30% of those still uncontrolled. That's ~160K patients, and at ~$30K net per year, roughly a $5B market.
Not all of that is up for grabs. Many of those patients will cycle through another biologic or a JAK first, and rezpeg would have to earn its place in that sequence. The niche won’t be uncontested either, as Pfizer is already testing tilrekimig in biologic-experienced patients.
But tilrekimig is still a type 2 drug. Rezpeg sitting outside the IL-4/IL-13 cascade and the JAK pathway gives it a real argument for patients who aren’t controlled on those drugs, and a path to substantial share of this niche.
But it has to prove it works there. That's why I see ZENITH AD-3 as the pivotal readout for Rezpeg's value. It's specifically enrolling patients previously treated with biologics and/or JAK inhibitors.
To be clear, $5B is the size of the niche where rezpeg is differentiated, not its total opportunity. It will pick up some biologic-naive patients too, but there it's competing in a crowded market without a clear edge. What could change that is durability.
4/5